Current Understanding on the Role of Standard and Immunoproteasomes in Inflammatory/Immunological Pathways of Multiple Sclerosis. (2nd January 2014)

• Record Type: Journal Article
• Authors: Bellavista, Elena; Santoro, Aurelia; Galimberti, Daniela; Comi, Cristoforo; Luciani, Fabio; Mishto, Michele
• Other Names: Dianzani Umberto Academic Editor.
• Is Part Of: Autoimmune diseases. Volume 2014(2014)
• Publication Date: 2014-01-02
• Subjects: Autoimmune diseases -- Periodicals; 571.97305
• DOI: 10.1155/2014/739705
• Languages: English
• ISSNs: 2090-0422

Abstract

Abstract : The ubiquitin-proteasome system is the major intracellular molecular machinery for protein degradation and maintenance of protein homeostasis in most human cells. As ubiquitin-proteasome system plays a critical role in the regulation of the immune system, it might also influence the development and progression of multiple sclerosis (MS). Both ex vivo analyses and animal models suggest that activity and composition of ubiquitin-proteasome system are altered in MS. Proteasome isoforms endowed of immunosubunits may affect the functionality of different cell types such as CD8 + and CD4 + T cells and B cells as well as neurons during MS development. Furthermore, the study of proteasome-related biomarkers, such as proteasome antibodies and circulating proteasomes, may represent a field of interest in MS. Proteasome inhibitors are already used as treatment for cancer and the recent development of inhibitors selective for immunoproteasome subunits may soon represent novel therapeutic approaches to the different forms of MS. In this review we describe the current knowledge on the potential role of proteasomes in MS and discuss the pro et contra of possible therapies for MS targeting proteasome isoforms.